- Home
- Implementing Heart Failure Guidelines with Collaborative Care
Implementing Heart Failure Guidelines with Collaborative Care
- Heart Failure
Available Credit:
- Not accredited
Course Published On:
Course Expiry Date:
Overview
This satellite symposium, presented and recorded at ESC 2023 in Amsterdam, by Prof Carolyn Lam (National Heart Centre Singapore, SG), provides an excellent opportunity to learn about the latest guideline recommendations in HFpEF and how to implement them effectively in clinical practice.
The panel of experts, including Dr Gianluigi Savarese (Karolinska Institute, Stockholm, SE), Dr Stephen Greene (Duke University School of Medicine, North Carolina, US), Prof Mark Petrie (University of Glasgow, Glasgow, UK) and Carys Barton (Imperial College Healthcare NHS Trust, London, UK) provide valuable insights into the challenges and barriers faced while adopting new guideline-directed medical therapy for heart failure patients. Collaborative care is an essential aspect of heart failure therapy and this session emphasises the significance of cross-functional teams in managing this condition.
Support Statement
This satellite symposium is supported by an unrestricted educational grant from AstraZeneca who had no involvement in the content.
Target Audience
- Cardiologists
- Heart Failure Specialists
- Primary Care Physicians
- Nurses, Pharmacists, and other Allied Healthcare Professionals
Learning Objectives
Upon completion of this activity, participants will be able to:
- Appraise new updates in heart failure guideline-directed medical therapy (GDMT)
- Apply latest guideline recommendations to patient cases
- Describe barriers preventing early initiation of GDMT
- Identify the roles of nurses and other healthcare professionals to achieve optimal heart failure therapy
- Identify the importance of the nurse/cross-functional team
Module |
Title |
Duration |
Speakers |
|---|---|---|---|
| Session 1 | Introduction and Part 1: Addressing New Guidelines | 20 mins | Carolyn Lam Mark Petrie Gianluigi Savarese Stephen J Greene Carys Barton |
| Session 2 | Early / Rapid Initiation of GDMT | 30 mins | Carolyn Lam Mark Petrie Gianluigi Savarese Stephen J Greene Carys Barton |
| Session 3 | Audience Q&A | 10 mins | Carolyn Lam Mark Petrie Gianluigi Savarese Stephen J Greene Carys Barton |
Introduction and Part 1: Addressing New Guidelines
Duration: 20 mins
Speakers: Carolyn Lam Mark Petrie Gianluigi Savarese Stephen J Greene Carys Barton
Early / Rapid Initiation of GDMT
Duration: 30 mins
Speakers: Carolyn Lam Mark Petrie Gianluigi Savarese Stephen J Greene Carys Barton
Audience Q&A
Duration: 10 mins
Speakers: Carolyn Lam Mark Petrie Gianluigi Savarese Stephen J Greene Carys Barton
Related Courses
- 1.00
Published:
Learning objectives
- Describe the current limitations of HFmrEF/HFpEF GDMT in advanced patients
- Select appropriate patients for advanced medical therapy
- Recall recent trial data for novel therapeutic approaches
- Use expert guidance to develop an evidence-based approach to managing advanced HFmrEF/HFpEF
- 1.25
Published:
Learning objectives
- To identify high-risk patient features indicative of worsening Heart Failure (HF)
- Name validated tools for serial prognostic assessment and risk stratification
- Adopt the use of appropriate assessment tools during patient follow-up
- Recall rates of recurrent HF events and their associated healthcare costs in worsening HF patients
- Recall the clinical benefit of emerging treatments targeted to treating worsening HF
- Initiate available treatment for the tailored management of worsening HF
- 1.00
Published:
Learning objectives
- Understand the nature of amyloidosis and its effects on various organs, particularly the heart
- Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
- Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
- Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
- Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
- Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team
- 0.50
Published:
Learning objectives
- Recall recent trial data for novel disease modifying therapy in HCM
- Describe the evolving guideline directed approach to managing HCM
- Develop an expert-led approach to implementing novel therapy in clinical practice
- Not accredited
Published:
Learning objectives
- Recall guideline recommendations for the use of NT-proBNP in heart failure
- Describe current practices in heart failure diagnosis and the impact on treatment outcomes
- Develop an optimised approach to the timely diagnosis and management of heart failure
- 2.00
Published:
Learning objectives
- Recall clinical evidence and guidelines for the management of CKD patients without diabetes
- Describe current gaps and barriers in evidence-based management for CKD without diabetes
- Apply evidence based-management strategies to a case study
- Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes
- Not accredited
Published:
Learning objectives
- Appraise the urgency needed in rapid initiation of GDMT to improve HF outcomes.
- Recognise barriers preventing the use of GDMT in current practice.
- Identify strategies needed to drive implementation of GDMT in clinical practice.
- Not accredited
Published:
Learning objectives
- Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
- Identify patients who would benefit from anti-hyperkalaemia medications
- Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
- Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
- Summarise current guideline recommendations on the use of potassium binding agents
- 1.00
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
- 1.00
Published:
Learning objectives
- Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
- Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
- Select appropriate imaging modalities to facilitate accurate risk stratification
- Stratify patients based on specific risk features and disease severity
- Choose suitable treatment modalities for patients based on specific disease features and severity